Subscribe To

Price Alert Latest News Economic Calendar News

CFRX / ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023

ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023

YONKERS, N.Y., June 08, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces that the Company has been selected to present four posters at the ASM Microbe Conference to be held in Houston, Texas from June 15-19, 2023. The data being presented will feature CF-370 demonstrating efficacious activity in a neutropenic rabbit pneumonia model against an extensively-drug-resistant (XDR) strain of Klebsiella pneumoniae (K. pneumoniae). Read More

Demo Live Account See Partner Details

Content Topics

Contrafect

Present

Data

Demonstrating

Potential

Efficacy

Engineered

Lysins

Against

Antibiotic resistant

Pathogens

Microbe

Stock

CFRX

Posted: Jun 8 2023, 16:01

Author Name: GlobeNewsWire

CFRX News

By InvestorPlace
October 16, 2023

Why Is ContraFect (CFRX) Stock Up 23% Today?

ContraFect (NASDAQ: CFRX ) stock is rising higher on Monday as investors react to an update from the Food and Drug Administration (FDA). The FDA has

By GlobeNewsWire
June 8, 2023

ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023

YONKERS, N.Y., June 08, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discover

By InvestorPlace
April 18, 2023

Why Is ContraFect (CFRX) Stock Down 14% Today?

ContraFect (NASDAQ: CFRX ) stock is dropping on Tuesday after the company revealed a notice from the Nasdaq Exchange. That notice has to do with the c

By InvestorPlace
January 31, 2023

Why Is ContraFect (CFRX) Stock Up 20% Today?

ContraFect (NASDAQ: CFRX ) stock is rising higher on Tuesday as investors await news about its potential delisting from the Nasdaq Capital Market. Con

By InvestorPlace
January 27, 2023

Why Is ContraFect (CFRX) Stock Down 23% Today?

ContraFect (NASDAQ: CFRX ) stock is falling on Friday after the company provided an update on its potential delisting from the Nasdaq Capital Market.

By InvestorPlace
July 14, 2022

Why Is ContraFect (CFRX) Stock Down 80% Today?

A Phase 3 trial of ContraFect's treatment for antibiotic-resistant infections has been stopped, and CFRX stock is plunging. The post Why Is ContraFect

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.